2023
Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger study
2016
Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis
Parian A, Limketkai B, Koh J, Brant SR, Bitton A, Cho JH, Duerr RH, McGovern DP, Proctor DD, Regueiro MD, Rioux JD, Schumm P, Taylor KD, Silverberg MS, Steinhart AH, Hernaez R, Lazarev M. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut 2016, 66: 1390. PMID: 27196594, PMCID: PMC5065377, DOI: 10.1136/gutjnl-2016-311550.Peer-Reviewed Original ResearchConceptsUC diagnosisDisease courseImpact of appendectomyRisk of colectomyTiming of appendectomyIndependent risk factorMilder disease courseSeverity of diseaseDevelopment of UCColectomy rateFuture colectomyEarly appendectomyClinical courseMultivariable analysisRisk factorsAppendectomyColectomyLarge cohortHigh riskPatientsDiagnosisConsortium databaseNational InstituteRiskUC
2013
EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging
Faubion WA, Fletcher JG, O'Byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. The American Journal Of Gastroenterology 2013, 108: 1891. PMID: 24126633, DOI: 10.1038/ajg.2013.354.Peer-Reviewed Original ResearchConceptsComputed tomography enterographySerum IL-22Disease activityFecal calprotectinCrohn's diseaseSerum MMP9Ulcerative colitisCross-sectional imagingCD patientsIL-22Serum matrix metalloproteinase-9Bowel wall inflammationInflammatory disease activitySerum interleukin‐22Inflammatory bowel diseaseFindings of inflammationCrohn's disease activityMatrix metalloproteinase-9Endoscopy subscoreTomography enterographyUC patientsEndoscopy scoresBowel diseaseClinical symptomsWall inflammationThe Influence of Depression on Quality of Life in Patients with Inflammatory Bowel Disease
Zhang CK, Hewett J, Hemming J, Grant T, Zhao H, Abraham C, Oikonomou I, Kanakia M, Cho JH, Proctor DD. The Influence of Depression on Quality of Life in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2013, 19: 1732-1739. PMID: 23669400, PMCID: PMC4623582, DOI: 10.1097/mib.0b013e318281f395.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseDisease activity indexHR-QOLCrohn's diseaseUlcerative colitisDisease activityBowel diseaseQuality of lifeActivity indexShort Inflammatory Bowel Disease QuestionnaireDepression InventoryInflammatory bowel disease practiceCrohn's Disease Activity IndexInflammatory Bowel Disease QuestionnairePatients' HR-QOLSeo activity indexBowel Disease QuestionnaireHealth-related qualityPoorer HR-QOLChronic inflammatory disordersPrevalence of depressionBeck Depression Inventory-IIDiagnosis of depressionCross-sectional studyImportance of depression